BNP Paribas Financial Markets reduced its holdings in Procena Inc. (NASDAQ:PRTA – Free Report ) by 65.4% during the first quarter, according to the latest disclosures filed with the Securities and Exchange Commission (SEC). The institutional investor sold 60,861 shares during the quarter and now owns 32,253 shares of the biotechnology company’s stock. BNP Paribas Financial Markets holds 0.06% of Procena Inc. worth $799,000 as of the latest SEC filing.
A number of other hedge funds also modified their holdings in PRTA. China Universal Asset Management increased its holdings in ProCena by 67.0% in the first quarter. China Universal Asset Management now holds 10,360 shares of the biotechnology company’s stock valued at $257,000. It acquired an additional 4,157 shares in the last quarter. Highmark Wealth Management LLC increased its holdings in ProCena by 124.5% in the first quarter. Highmark Wealth Management LLC now holds 16,502 shares of the biotechnology company’s stock valued at $409,000. It acquired an additional 9,150 shares in the last quarter. PNC Financial Services Group increased its holdings in ProCena by 265.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,544 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,122 shares during the period. Wellington Management Group Inc. increased its holdings in Procena by 21.1% in the fourth quarter. Wellington Management Group Inc. now owns 2,594,102 shares of the biotechnology company’s stock valued at $94,270,000 after purchasing an additional 452,455 shares in the last quarter. Finally, Price T. Rowe Associates Inc. increased its holdings in Procena by 10.9% in the fourth quarter. Price T. Rowe Associates Inc. now owns 4,237,351 shares of the biotechnology company’s stock valued at $153,986,000. This comes after an additional purchase of 417,338 shares in the last quarter. 97.08% of the stock is now held by institutional investors.
Analyst Rating Changes
PRTA has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed their “overweight” rating on shares of Prosena in a research note on Wednesday, April 10th. HC Wainwright lowered their price target on Prosena from $90.00 to $84.00 and set a “buy” rating on the company in a research note on Thursday, May 9th. JMP Securities lowered their price target on Prosena from $85.00 to $83.00 and set a “market outperform” rating on the company in a report on Thursday, May 9th. Finally, Royal Bank of Canada reaffirmed their “sector perform” rating on shares of Prosena and set a $28.00 price target in a report on Wednesday, June 26th. One analyst has rated the stock with a sell rating, two have rated it with a hold rating, and five have rated it with a buy rating. According to MarketBeat data, Prothena currently has a consensus rating of “Moderate Buy” and an average target price of $66.00.
Read the latest Prothena research report
Procena’s price performance
PRTA shares opened at $23.58 on Friday. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -7.26 and a beta of 0.21. The stock’s 50-day simple moving average is $21.21 and its 200-day simple moving average is $25.12. Prothena Co. plc’s low over the past year is $18.69 and its high over the past year is $70.09.
Prothena (NASDAQ:PRTA – get free report ) announced its quarterly earnings on Wednesday, May 8th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.13). Prothena had a return on equity of -30.48% and a net margin of -193.17%. The company’s quarterly revenue was $0.05 million, missing the consensus estimate of $3.75 million. During the same period last year, the company’s earnings per share were ($0.89). Equity research analysts expect Prothena Co. plc to post -4.54 EPS for the current year.
ProCena Profile
(Free report)
Prothena Corporation plc, a late-stage clinical biotechnology company, is focused on discovering and developing novel therapeutics to treat diseases caused by protein dysregulation in the U.S. The company is developing virutamimab, an investigational humanized antibody in Phase III clinical trials for the treatment of AL amyloidosis, prasinezumab, a humanized monoclonal antibody in Phase IIb clinical trials for the treatment of Parkinson’s disease and other related synucleinopathies, NNC6019 in Phase III clinical trials for the treatment of ATTR amyloidosis, and BMS-986446 and PRX012 in Phase I clinical trials for the treatment of Alzheimer’s disease.
reference
Get Prothena News and Ratings Daily – Enter your email address below to receive a concise summary of the latest news and analyst ratings on Prothena and related companies every day with MarketBeat.com’s free email newsletter.
